Trinity Biotech (Trinity Biotech) COGS-to-Revenue : 0.66 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech COGS-to-Revenue?

Trinity Biotech's Cost of Goods Sold for the three months ended in Dec. 2023 was $8.86 Mil. Its Revenue for the three months ended in Dec. 2023 was $13.43 Mil.

Trinity Biotech's COGS to Revenue for the three months ended in Dec. 2023 was 0.66.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Trinity Biotech's Gross Margin % for the three months ended in Dec. 2023 was 34.01%.

Trinity Biotech COGS-to-Revenue Historical Data

The historical data trend for Trinity Biotech's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech COGS-to-Revenue Chart

Trinity Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.58

0.52

0.59

0.72

0.66

Trinity Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.66	0.62	0.64	0.71	0.66

Trinity Biotech COGS-to-Revenue Calculation

Trinity Biotech's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	37.382	/	56.832
	=	0.66

Trinity Biotech's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	8.861	/	13.428
	=	0.66

Trinity Biotech (NAS:TRIB) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Trinity Biotech's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	8.861 / 13.428
	=	34.01 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Trinity Biotech COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (Trinity Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » COGS-to-Revenue

Comparable Companies

STRR CNTG CHEK PMD MYNZ SLDX PRPO XWEL PCHM DMTK TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

TRBA:Germany

Address

IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website

https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.